학술논문
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study
Document Type
article
Author
Monique K. van der Kooij; Olaf M. Dekkers; Maureen J. B. Aarts; Franchette W. P. J. van den Berkmortel; Marye J. Boers-Sonderen; Jan Willem B. de Groot; Geke A. P. Hospers; Djura Piersma; Rozemarijn S. van Rijn; Karijn P. M. Suijkerbuijk; Hans M. Westgeest; Astrid A. M. van der Veldt; Gerard Vreugdenhil; Sofie Wilgenhof; Michel W. J. M. Wouters; John B. A. G. Haanen; Alfonsus J. M. van den Eertwegh; Ellen Kapiteijn
Source
Cancers, Vol 13, Iss 18, p 4639 (2021)
Subject
Language
English
ISSN
2072-6694
Abstract
Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013–July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3–4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.